乳腺导管原位癌与人表皮生长因子受体-2关系的研究进展

Advances in the relationship between ductal carcinoma in situ of the breast and human epidermal growth factor receptor-2

乳腺癌现已成为全球恶性肿瘤中恶性程度较高的一种肿瘤。并且它存在很多种亚型,其中乳腺导管原位癌是一种特殊类型的肿瘤,它是一种原位非浸润性癌。在大多数情况下通过X线筛查发现,临床症状不明显,只有少部分患者会出现乳房肿块或乳房皮肤改变等症状。而在乳腺导管原位癌中检测出的人表皮生长因子受体-2分子与较高的复发风险有一定的关系,可使乳腺导管原位癌进展为乳腺浸润性癌,大大提高肿瘤的恶性程度。这一分子与乳腺导管原位癌的预后复发及治疗存在很大的关系。目前临床上也无明确针对乳腺导管原位癌的治疗方法,大多数情况下采用手术切除或辅助放化疗等方式治疗。本文就乳腺导管原位癌的病理特征、预后及治疗与人表皮生长因子受体-2这一分子关系的研究进展作一综述。

Breast cancer has become one of the most malignant tumors in the world.And it exists many subtypes,of which ductal carcinoma in situ is a special type of tumor,and it is a non-invasive carcinoma in situ.In most cases,it is detected by X-ray screening,and the clinical symptoms are not obvious,and only a small number of patients will have symptoms such as breast lumps or breast skin changes.Human epidermal growth factor receptor-2 molecules detected in ductal carcinoma in situ are associated with a higher risk of recurrence,which can make ductal carcinoma in situ progress into breast invasive cancer and greatly improve the malignant degree of the tumor.This molecule is closely related to the prognosis and treatment of ductal carcinoma in situ.At present,there is no clear treatment method for breast ductal carcinoma in situ in clinical practice,and most cases are treated by surgical resection or adjuvant chemoradiation.This review reviews the relationship between the pathological features,prognosis and treatment of ductal carcinoma in situ of the breast and human epidermal growth factor receptor-2.